← Eichor
Condition: Advanced Neuroendocrine Neoplasm Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Neuroendocrine Neoplasm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Phase 1/Phase 2 · 11 location(s) · National Health Research Institutes, Taiwan · NCT05048901Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Hangzhou Hanx Biopharmaceuticals, Ltd. · NCT06708663Neoadjuvant Tebentafusp for Uveal Melanoma
Phase 2 · 2 location(s) · Thomas Jefferson University · NCT06414590Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Phase 1 · 1 location(s) · Loyola University · NCT02870244An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancr
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05884255BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033APA (Adapted Physical Activity) for Patients With Advanced Melanoma
Phase N/A · 1 location(s) · University Hospital, Rouen · NCT07031830Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followe
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06440057Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Phase 2 · 9 location(s) · Jazz Pharmaceuticals · NCT07282587Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 · 10 location(s) · Circle Pharma · NCT06577987Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · Georgiamune Inc · NCT06425926At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanom
Phase 1 · 2 location(s) · Yana Najjar · NCT04572451A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Phase 1/Phase 2 · 9 location(s) · NuCana plc · NCT03829254NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Phase 1 · 2 location(s) · Centre Hospitalier Universitaire Vaudois · NCT06889766A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0
Phase 2 · 38 location(s) · Merck Sharp & Dohme LLC · NCT06961006Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06961357Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Phase 2 · 1 location(s) · Melanoma Institute Australia · NCT06999980Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
EARLY_Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04741997A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Axitinib + Ipilimumab in Advanced Melanoma
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04996823IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Phase 1 · 2 location(s) · TuHURA Biosciences, Inc. · NCT06940440Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698TARGETed Therapy Drug MONITOring in DIGestive Oncology
NA · 29 location(s) · UNICANCER · NCT05443087
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.